Bli medlem
Bli medlem

Du är här


Medivir: Invitation to conference call and webcast today 3 November, at 14.30 CET

Medivir will be conducting an analyst and investor conference
call/webcast today 3 November, at 14.30 CET. Niklas Prager CEO, Ola
Burmark CFO and Richard Bethell CSO will be presenting and will be
available for questions relating to the recent agreement to acquire
two clinical stage oncology programs from Tetralogic Pharmaceuticals

To join the conference call, please dial:
Sweden +46 (0)8 566 426 96
Europe +44 20 300 898 17
USA +1 855 831 5946
The webcast can be accessed on the website:

For further information, please contact:
Niklas Prager, CEO and President Medivir AB, +46 8 407 6430
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Richard Bethell, CSO Medivir AB, mobile +46 (0)72 704 3211
About Medivir
Medivir is a research based pharmaceutical company with a research
focus on oncology and infectious diseases. We have a leading
competence within protease inhibitor design and nucleotide/nucleoside
science and we are dedicated to develop innovative pharmaceuticals
that meet great unmet medical need. Our commercial organization
provides a portfolio of specialty care pharmaceuticals on the Nordic
market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.